Patents Examined by Vanessa L. Ford
  • Patent number: 11384143
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: July 12, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Patent number: 11369663
    Abstract: The present disclosure provides for methods and compositions for the modulation of CD5 in a subject. Also provided are methods of detecting and monitoring diseases, such as inflammatory and autoimmune diseases.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: June 28, 2022
    Assignee: Washington University
    Inventor: Eynav Klechevsky
  • Patent number: 11357827
    Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 14, 2022
    Assignee: Genexine, Inc.
    Inventors: Moon Cheol Kang, Young Woo Choi, Donghoon Choi, Young Chul Sung
  • Patent number: 11353465
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: June 7, 2022
    Assignee: Astute Medical, Inc.
    Inventors: James Patrick Kampf, Paul McPherson, Donald Chalfin
  • Patent number: 11344603
    Abstract: The inventions relate to the use of hemichannel blockers to modulate cytokine levels in a subject, including the angiogenic cytokine, VEGF, and their production, secretion and/or release, and to the use of hemichannel blockers to reduce or level cytokine activity, including in conditions characterized in whole or in part by angiogenesis and/or vessel leak.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 31, 2022
    Assignees: AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin Richard Green, Odunayo Omolola Boluwarin Mugisho, Bradford James Duft
  • Patent number: 11346846
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Metalloproteinase inhibitor 1, Metalloproteinase inhibitor 2, Metalloproteinase inhibitor 4, C—C motif chemokine 15, C—C motif chemokine 18, C—C motif chemokine 23, and/or, C—C motif chemokine 24 as diagnostic and prognostic biomarker assays in renal injuries.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 31, 2022
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Paul McPherson, James Patrick Kampf, Kevin Nakamura, Jeff Gray, Thomas Kwan
  • Patent number: 11333671
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C—C motif chemokine 16, C—C motif chemokine 14, and Tyrosine-protein kinase receptor UFO as diagnostic and prognostic biomarker assays in renal injuries.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: May 17, 2022
    Assignee: ASTUTE MEDICAL, INC.
    Inventors: Joseph Anderberg, Paul McPherson, Jeff Gray, Kevin Nakamura, James Patrick Kampf, Thomas Kwan
  • Patent number: 11332521
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 17, 2022
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae Young Seong, Jong Ik Hwang, Eun Bee Cho, Junho Chung, Junyeong Jin, Tae Young Yune, Jee Youn Lee
  • Patent number: 11331388
    Abstract: Methods of treating fibrotic diseases and disorders including Systemic sclerosis (SSc) are provided. Methods include, for example, administering to a subject an effective amount of an antagonist/inhibitor of PTP4A1 protein expression or activity to treat a fibrotic disease or disorder such as SSc, or an associated pathology such as organ or skin fibrosis.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: May 17, 2022
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Nunzio Bottini, Cristiano Sacchetti, Stephanie M. Stanford
  • Patent number: 11331374
    Abstract: The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 17, 2022
    Assignee: NYMOX CORPORATION
    Inventor: Paul Averback
  • Patent number: 11304993
    Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: April 19, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventors: Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
  • Patent number: 11306140
    Abstract: Methods and compositions for reducing the activity or number of memory Th17 cells in ocular tissue, and for treatment and/or prevention of ocular immunoinflammatory diseases are described.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 19, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Sunil Chauhan, Yihe Chen
  • Patent number: 11291709
    Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: April 5, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventors: Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
  • Patent number: 11278593
    Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 22, 2022
    Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: Matthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'Neill
  • Patent number: 11278629
    Abstract: Methods for identifying and treating patients having cancer who are likely to respond to treatment with an anti-CD37 immunoconjugate (e.g., IMGN529) are provided.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 22, 2022
    Assignee: DEBIOPHARM INTERNATIONAL, S.A.
    Inventors: Francesco Bertoni, Angela Romanelli, Callum Sloss
  • Patent number: 11261225
    Abstract: Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: March 1, 2022
    Assignee: INSTITUTE FOR CANCER RESEARCH
    Inventors: Roland L. Dunbrack, Jared Adolf-Bryfogle, Gregory P. Adams, Matthew K. Robinson
  • Patent number: 11260027
    Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 1, 2022
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Satish Nadig, Carl Atkinson, Ann-Marie Broome, Suraj K. Dixit
  • Patent number: 11241497
    Abstract: The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 8, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Sunil Chauhan
  • Patent number: 11243217
    Abstract: The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: February 8, 2022
    Assignees: Astute Medical, Inc., University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Paul McPherson, James Patrick Kampf, John A. Kellum
  • Patent number: 11243202
    Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: February 8, 2022
    Assignees: ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER
    Inventors: Paul McPherson, John A. Kellum, Jr., Alexander Zarbock